<DOC>
	<DOCNO>NCT00045318</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase I trial study effectiveness exatecan mesylate treat patient advance solid tumor kidney dysfunction .</brief_summary>
	<brief_title>Exatecan Mesylate Treating Patients With Advanced Solid Tumors Kidney Dysfunction</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose exatecan mesylate patient advance solid tumor vary degree renal dysfunction . - Determine dose-limiting non-dose-limiting toxic effect drug patient . - Determine effect renal dysfunction plasma pharmacokinetics pharmacodynamics drug patient . - Establish model dose drug patient impaired renal function . OUTLINE : This dose-escalation , multicenter study . Patients stratify accord severity renal dysfunction ( normal v mild v moderate v severe ) . Patients receive exatecan mesylate IV 30 minute day 1-5 . Courses repeat every 3 week absence disease progression unacceptable toxicity . Cohorts 3-6 patient renal dysfunction stratum receive escalate dos exatecan mesylate maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . Patients normal renal function stratum undergo dose escalation . Patients follow every 3 month . PROJECTED ACCRUAL : A total 45 patient ( 6 normal , 9 mild , 12 moderate , 18 severe renal dysfunction ) accrue study within 1.5 year .</detailed_description>
	<mesh_term>Exatecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm advanced solid tumor refractory standard therapy standard therapy exist Renal function define follow parameter : Normal ( creatinine clearance ( CrCl ) great 80 mL/min ) Mild dysfunction ( CrCl 5080 mL/min ) Moderate dysfunction ( CrCl 3050 mL/min ) Severe dysfunction ( CrCl le 30 mL/min ) Endstage renal disease ( require dialysis ) No symptomatic active brain metastasis ( e.g. , edema progression CT scan MRI ) PATIENT CHARACTERISTICS : Age 18 Performance status ECOG 02 Life expectancy At least 12 week Hematopoietic Absolute neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 Hemoglobin least 9.0 g/dL Hepatic Bilirubin normal AST ALT great 2 time upper limit normal Albumin least 2.8 g/dL Renal See Disease Characteristics Cardiovascular No active congestive heart failure No uncontrolled angina No myocardial infarction within past 6 month Other No concurrent serious infection No lifethreatening illness No overt psychosis mental disability incompetency would preclude informed consent Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy No concurrent anticancer biologic therapy Chemotherapy At least 4 week since prior chemotherapy ( 6 week mitomycin nitrosourea ) recover No prior exatecan mesylate No concurrent anticancer chemotherapy Endocrine therapy No concurrent anticancer hormonal therapy Concurrent megestrol appetite stimulation allow Radiotherapy At least 4 week since prior radiotherapy recover No concurrent anticancer radiotherapy Surgery At least 4 week since prior major surgery recover No concurrent anticancer surgery Other At least 4 week since prior investigational drug include analgesic antiemetic At least 1 week since prior grapefruit juice No concurrent anticancer therapy No investigational drug 4 week study No concurrent grapefruit juice No concurrent anticancer cytotoxic therapy Concurrent chronic hemodialysis ambulatory peritoneal dialysis allow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2003</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>